Dr. Madhavi Nagilla, MD

Dr. Nagilla practices at Mercer Bucks Medical Associates in Trenton, New Jersey.

Dr. Nagilla's NPI, 1639314834, was assigned on December 3, 2008. Dr. Nagilla holds Illinois license 036.129619.

Dr. Nagilla's primary practice is Mercer Bucks Medical Associates, at 1760 Whitehorse Hamilton Square Rd, Trenton, NJ 08690 in Mercer County. The practice phone is (609) 586-6678.

Dr. Nagilla's primary practice is Mercer Bucks Medical Associates in Trenton, New Jersey. Dr. Nagilla is also affiliated with St. Mary Medical Center. The medical group on file is First Docs. Dmand AI also links Dr. Nagilla to 3 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nagilla practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Nagilla's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Nagilla is licensed in Illinois.

CMS data shows 159 Medicare services from Dr. Nagilla across 3 procedure codes in 2024, for 71 Medicare patients. Medicare paid $13,151 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 71 Medicare patients who saw Dr. Nagilla in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 45% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nagilla's median patient age at 76, with 56% women.

In 2024, Dr. Nagilla wrote 115 Medicare Part D claims for 30 patients. 83% of them were for generic drugs. CMS names the drug for 18 of them, across 1 drug with 11 or more claims each, at $105 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Nagilla for performance year 2024, reported as part of a group. Dr. Nagilla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nagilla as offering telehealth.

Dmand AI links 4 papers to Dr. Nagilla, published from 2012 to 2015. 2014 was the busiest year, with 2. The most frequent topics are Antineoplastic Agents, Class I Phosphatidylinositol 3-Kinases and Phosphatidylinositol 3-Kinases. Dr. Nagilla's most frequent co-authors are Ezra E. Cohen, MD, Jing Ming Liu, MD and Marina Nasrin Sharifi, MD, PhD.

CMS Open Payments shows 44 general payments to Dr. Nagilla from 20 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Janssen Pharmaceuticals, Inc paid the most, $209.